The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors.
 
Alexander Starodub
Consulting or Advisory Role - Bayer; Sandoz
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Sandoz
 
Nashat Y. Gabrail
Consulting or Advisory Role - Celgene; Chemiocare
Speakers' Bureau - Janssen Oncology; Karyopharm Therapeutics; Taiho Pharmaceutical; Tesaro/GSK
Research Funding - Amgen (Inst); Bayer (Inst); Chemiocare (Inst); Kartos Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Oncology Supply
 
Ying Zhang
Employment - Ascendis Pharma
Stock and Other Ownership Interests - Ascendis Pharma
 
Davis Y Torrejon Castro
Employment - Ascendis Pharma
Stock and Other Ownership Interests - Ascendis Pharma
 
Sibel Slavsky
Employment - Ascendis Pharma; Nektar
Stock and Other Ownership Interests - Ascendis Pharma; Nektar
 
Stina Mui Singel
Employment - Ascendis Pharma; Nektar
Stock and Other Ownership Interests - Ascendis Pharma; Nektar
Patents, Royalties, Other Intellectual Property - Patent for Novel cancer treatments with TLR7/8 Agonist filed Dec 2021
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Carolina BioOncology Institute
Consulting or Advisory Role - Aavocyte; Abbvie; AstraZeneca/MedImmune; Boxer Capital; Genentech/Roche; Phanes Therapeutics; TERUMO; TopAlliance BioSciences Inc
Research Funding - Abbvie; Adagene (Inst); Alkermes; Apros Therapeutics; Arcus Biosciences; Ascendis Pharma (Inst); AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Conjupro Biotherapeutics (Inst); Corvus Pharmaceuticals; Cullinan Oncology (Inst); Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); Fate Therapeutics (Inst); FLX Bio; Function Oncology (Inst); Genentech/Roche; I-Mab (Inst); Immune-Onc Therapeutics (Inst); Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); Molecular Templates (Inst); MT Group (Inst); NextCure (Inst); Nuvation Bio (Inst); Pioma Chemicals (Inst); Precision for Medicine (Inst); Repertoire Immune Medicines (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience; Trethera (Inst); Xilio Therapeutics (Inst); Xilis (Inst); Zenshine (Inst)
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy